Silvercorp Metals announced a normal course issuer bid starting September 21, 2026, to buy back up to 8.85 million common shares, about 4% of its outstanding shares. The program aims to provide flexibility if the stock is undervalued relative to its mining assets and will run until September 20, 2027. Purchases will be made at market prices on Canadian and U.S. exchanges, with all repurchased shares to be cancelled. This move follows a similar program in 2025, which saw no share repurchases, signaling Silvercorp's intent to enhance shareholder value through strategic buybacks.
Silvercorp Metals' share repurchase program is the subject, with Pluang's Basic Materials sector data providing market context. As of Sep 17, 2026 19:11 WIB, 27 of 31 US Basic Materials stocks rose while 4 fell. Notable movers include FCX at USD 71.29 with a 1-day change of +2.94%, LAC at USD 2.86 with +2.88%, and ALB at USD 112.31 with +2.59%.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
